top of page

TRANSFAL
SUB-STUDY OF PREDICTIVE BIOMARKERS FOR PALBOCICLIB AND ENDOCRINE THERAPY IN ER+/HER2- ADVANCED BREAST CANCER

CLINICAL TRIAL DETAILS
THE TRANSFAL PROJECT IS A SUB-STUDY WITHIN THE PARSIFAL CLINICAL TRIAL. THE INITIAL GOAL WILL BE TO ANALYZE THE MOLECULAR TUMOR PROFILE AT THE TIME OF PROGRESSION IN PATIENTS WITH MODERATE SENSITIVITY TO PALBOCICLIB IN COMBINATION WITH FIRST-LINE ENDOCRINE THERAPY. FOR THIS PURPOSE, DIFFERENT MOLECULAR APPROACHES, SUCH AS DIFFERENTIAL PROTEOMICS, IN VIVO PDX MODELS, FISH, DNA SEQUENCING, WILL BE RUN ON AN INITIAL SUBSET OF THE PARSIFAL POPULATION.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
BREAST
52
280
Sub-study
Spain, France, Italy, UK, Germany, Czech Republic, Russia
Closing
TRIAL OVERVIEW
PRESS RELEASE
----
SCIENTIFIC IMPACT
AACR 2024 - PARSIFAL-LONG substudy (transFAL) lay language sâummary
AACR - PARSIFAL-LONG substudy (transFAL) poster
BLOG ARTICLES RELATED
Dr. Marta Palafox presents results from the TRANSFAL sub-study at ESMO 2020
MEDSIR to present results of two of our research projects this year at ESMO 2020!
TRIAL SITES
----
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi AntolĂn
Dr. EscrivĂĄ de RomanĂ
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page
